HIMS loses weight in premarket trade
Wall Street Breakfast
00:00
HIMS stops compounded GLP-1 offering
Julie Morgan reports HIMS will discontinue its compounded copycat of Novo Nordisk’s Wegovy after FDA scrutiny and industry talks.
Play episode from 00:15
Transcript
